BidaskClub Upgrades Strongbridge Biopharma (SBBP) to Strong-Buy

BidaskClub upgraded shares of Strongbridge Biopharma (NASDAQ:SBBP) from a buy rating to a strong-buy rating in a research note released on Thursday morning.

Several other equities research analysts have also recently weighed in on the company. Zacks Investment Research cut Strongbridge Biopharma from a hold rating to a sell rating in a research report on Friday, March 16th. Cantor Fitzgerald reiterated a buy rating and set a $14.00 price target on shares of Strongbridge Biopharma in a research report on Monday, March 12th. Finally, HC Wainwright reiterated a buy rating and set a $18.00 price target on shares of Strongbridge Biopharma in a research report on Thursday, January 18th. Two research analysts have rated the stock with a sell rating, three have given a buy rating and one has given a strong buy rating to the company’s stock. The stock currently has an average rating of Buy and an average price target of $12.81.

How to Become a New Pot Stock Millionaire

Shares of Strongbridge Biopharma stock opened at $8.05 on Thursday. Strongbridge Biopharma has a 52-week low of $3.50 and a 52-week high of $9.02. The company has a debt-to-equity ratio of -3.17, a quick ratio of 4.84 and a current ratio of 4.88.

Several hedge funds and other institutional investors have recently modified their holdings of the company. Caxton Corp grew its holdings in shares of Strongbridge Biopharma by 2.2% during the third quarter. Caxton Corp now owns 5,514,994 shares of the biotechnology company’s stock worth $38,053,000 after purchasing an additional 120,000 shares in the last quarter. Broadfin Capital LLC grew its holdings in shares of Strongbridge Biopharma by 10.4% during the fourth quarter. Broadfin Capital LLC now owns 3,186,695 shares of the biotechnology company’s stock worth $23,104,000 after purchasing an additional 299,900 shares in the last quarter. Armistice Capital LLC grew its holdings in shares of Strongbridge Biopharma by 69.4% during the fourth quarter. Armistice Capital LLC now owns 2,870,000 shares of the biotechnology company’s stock worth $20,808,000 after purchasing an additional 1,175,400 shares in the last quarter. BlackRock Inc. grew its holdings in shares of Strongbridge Biopharma by 57.5% during the fourth quarter. BlackRock Inc. now owns 1,432,365 shares of the biotechnology company’s stock worth $10,385,000 after purchasing an additional 522,875 shares in the last quarter. Finally, Lyon Street Capital LLC grew its holdings in shares of Strongbridge Biopharma by 239.0% during the fourth quarter. Lyon Street Capital LLC now owns 1,406,095 shares of the biotechnology company’s stock worth $10,194,000 after purchasing an additional 991,322 shares in the last quarter. 57.63% of the stock is owned by institutional investors.

COPYRIGHT VIOLATION WARNING: This report was originally reported by Ticker Report and is the sole property of of Ticker Report. If you are viewing this report on another publication, it was illegally copied and reposted in violation of United States & international trademark & copyright laws. The legal version of this report can be viewed at https://www.tickerreport.com/banking-finance/3298938/bidaskclub-upgrades-strongbridge-biopharma-sbbp-to-strong-buy.html.

Strongbridge Biopharma Company Profile

Strongbridge Biopharma plc is a global commercial-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies for a range of diseases. The Company’s commercial product, KEVEYIS (dichlorphenamide), is indicated for the treatment of hyperkalemic, hypokalemic and related variants of primary periodic paralysis.

Receive News & Ratings for Strongbridge Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Strongbridge Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Whiting Petroleum  Sets New 52-Week High and Low at $40.47
Whiting Petroleum Sets New 52-Week High and Low at $40.47
SilverBow Resources  Reaches New 52-Week High and Low at $34.76
SilverBow Resources Reaches New 52-Week High and Low at $34.76
Financial Comparison: Service Co. International  versus Yelp
Financial Comparison: Service Co. International versus Yelp
Critical Contrast: Morgan Stanley  and Its Competitors
Critical Contrast: Morgan Stanley and Its Competitors
Barfresh Food Group  vs. Lamb Weston  Head to Head Survey
Barfresh Food Group vs. Lamb Weston Head to Head Survey
Royal Bank of Canada Increases American Express  Price Target to $86.00
Royal Bank of Canada Increases American Express Price Target to $86.00


© 2006-2018 Ticker Report. Google+.